USPTO serial 87017926
METADICHOL
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 20, 2016
- Examiner
- KUNG, KAELIE ELIZABETH
- Law office
- TMEG LAW OFFICE 103
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with METADICHOL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*
Plus Government fees of $650
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Chappaqua, NY, US
Chappaqua, NY, US
Chappaqua, NY, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Scott D. Locke
Scott D. Locke DORF NELSON & ZAUDERER LLP555 THEODORE FREMD AVE.THE INTERNATIONAL CORPORATE CENTERRYE, NY 10580Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Analgesic and muscle relaxant nutraceutical preparations; Anti-diabetic nutraceuticals; Cardiovascular nutraceuticals; Nutraceutical preparations for the treatment of gout; Nutraceutical preparations and substances for the treatment of gastro-intestinal diseases; Nutraceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Nutraceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Nutraceutical preparations for inhalation for the treatment of pulmonary hypertension; Nutraceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Nutraceutical preparations for the treatment of inflammatory disorders; Nutraceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Nutraceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Nutraceutical preparations for the prevention of diabetes; Nutraceutical preparations for the treatment of eye diseases and conditions; Nutraceutical preparations for the treatment of heart rhythm disorders; Nutraceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Nutraceutical preparations for the treatment of infectious diseases; Nutraceutical preparations for the treatment of hypertension; Nutraceutical preparations for treating allergic rhinitis and asthma; Nutraceutical preparations for treating diabetes; Nutraceutical preparations for treating skin disorders; Nutraceutical preparations for use in urology; Nutraceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Nutraceutical products for ophthalmological use; Nutraceutical products for the treatment of bone diseases; Nutraceutical products for the treatment of joint disease; Nutraceutical products for the treatment of viral and infectious diseases; Nutraceutical preparations for the treatment of cancer; Nutraceutical products for treating respiratory diseases and asthma; Nutraceutical solutions used in dialysis; Nutraceuticals, namely, lipid lowering agents; Plant extracts for medical, veterinary and nutraceutical purposes; Therapeutic nutraceuticals for the treatment of obesity | ACTIVE | Jun 10, 2010 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 13, 2026 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Dec 20, 2025 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| May 18, 2023 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| May 18, 2023 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| May 18, 2023 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Nov 3, 2022 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Dec 20, 2021 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Dec 20, 2016 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 4, 2016 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 4, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 4, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 14, 2016 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 30, 2016 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Aug 30, 2016 | ALIE | ASSIGNED TO LIE | — |
| Aug 15, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 15, 2016 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 15, 2016 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 15, 2016 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 15, 2016 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 15, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| May 2, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 2, 2016 | NWAP | NEW APPLICATION ENTERED | — |